D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $15.00 price objective on the stock. D. Boral Capital’s target price points to a potential upside of 217.12% from the stock’s previous close.

A number of other brokerages have also issued reports on COYA. Lake Street Capital restated a “buy” rating and set a $17.00 target price on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. BTIG Research lifted their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a report on Monday, November 24th. Finally, Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Coya Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Stock Performance

COYA opened at $4.73 on Wednesday. Coya Therapeutics has a one year low of $3.94 and a one year high of $8.29. The stock has a market capitalization of $98.95 million, a P/E ratio of -4.26 and a beta of 0.25. The business’s 50-day simple moving average is $5.56 and its 200-day simple moving average is $5.95.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. On average, equities research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of COYA. JPMorgan Chase & Co. purchased a new stake in Coya Therapeutics during the third quarter worth $28,000. Lantern Wealth Advisors LLC purchased a new stake in shares of Coya Therapeutics in the 3rd quarter worth about $66,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Coya Therapeutics in the 2nd quarter worth about $119,000. Prosperity Wealth Management Inc. grew its stake in Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after acquiring an additional 3,350 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after acquiring an additional 13,176 shares in the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.